LATEST

FDA approves Bayer’s Bluetooth-enabled auto-injector for multiple sclerosisFDA has approved a supplemental Biologics License Application (sBLA) for Bayer’s myBETAapp and BETACONNECT Navigator for multiple sclerosis (MS) patients
FDA to drug maker: Pull opioid pain drugPotential public health consquences prompts FDA to request removal of opioid pain medication.
FDA approves EpiPen rivalAdamis’ epinephrine injection promises to be a lower-cost alterative to EpiPen.
Asthma biologic may reduce oral steroid useA new trial for AstraZeneca’s benralizumab shows promising results for severe asthma patients.
Investigational drug appears beneficial in preventing migrainesLilly's galcanezumab proves successful in three phase 3 migraine studies. Here are the findings.
Drugmaker recalls samples of antiplatelet drugAstraZeneca voluntarily recalls professional samples of its antiplatelet agent. Here's what to do.
Top 5 specialty drug management issuesThe 13th edition EMD Serono Specialty Digest outlines top specialty drug management issues health plans face.
How pharma reps impact physician prescribingA new study led by The University of California researchers and published in JAMA reveals surprising findings.
Amputation risk possible with diabetes drugs, FDA warnsBased on new data from 2 large clinical trials, FDA is warning that these blockbuster type 2 diabetes medications can cause an increased risk of leg and foot amputations.
New FDA lead ushers in new eraScott Gottlieb, MD, was sworn in as the new FDA commissioner and ushers in a new era.

Poll

View Results